Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes.
Postprandial lipoproteins are raised in diabetes and there is increasing evidence for the atherogenicity of the chylomicron remnant. Increased postprandial cholesteryl ester transfer has also been demonstrated in diabetes and may contribute to the atherogenic lipoprotein profile. The present study examined the effect of improving metabolic control on postprandial lipoproteins in 13 Type 2 diabetic patients. Blood was taken fasting and at 2-h intervals following a high fat, 1100 kcal meal. Patients were brought into good control by intensified dietary advice and oral hyperglycaemic agents or insulin if blood glucose failed to respond. Fasting and postprandial cholesteryl ester transfer protein (CETP) and lecithin:cholesteryl acyltransferase (LCAT) were determined in six patients. Lipoproteins were isolated by sequential ultracentrifugation. Chylomicron and very low density lipoprotein (VLDL) apolipoprotein B-48 and apolipoprotein B-100 were isolated by polyacrylamide gradient gel electrophoresis and quantified by densitometric scanning. CETP and LCAT were determined by an endogenous method which determined cholesterol esterification and transfer between the patients' lipoproteins. There was a significant reduction in postprandial chylomicron apo B-48 (P<0.005), apo B-100 (P<0.0005) and chylomicron cholesterol (P<0.001) following improved diabetic control. The chylomicron lipid/apo B ratio increased with improved control (P<0.01). Postprandial CETP and LCAT were significantly reduced in good control (P<0.01 and P<0.05, respectively) and there were significant changes in HDL composition. The study shows that improvement in metabolic control in Type 2 diabetic patients leads to a reduction in postprandial chylomicron particles and less transfer of cholesterol to apo B-containing lipoproteins.
Phillips
C
C
Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
Murugasu
G
G
Owens
D
D
Collins
P
P
Johnson
A
A
Tomkin
G H
GH
D000368:Aged; D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B / Q000032:analysis / Q000097:blood*; D002352:Carrier Proteins / Q000097:blood; D002784:Cholesterol / Q000032:analysis; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL / Q000737:chemistry; D002914:Chylomicrons / Q000737:chemistry; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism* / Q000628:therapy*; D004435:Eating / Q000502:physiology*; D005215:Fasting / Q000502:physiology; D005260:Female; D006023:Glycoproteins; D006801:Humans; D008055:Lipids / Q000032:analysis; D008297:Male; D008875:Middle Aged; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood
D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D002914:Chylomicrons; D006023:Glycoproteins; D008055:Lipids; D002784:Cholesterol; D007862:Phosphatidylcholine-Sterol O-Acyltransferase